Low physiological pH drives P300-mediated acetylation of PARP1 and promotes PARP inhibitor resistance [RNA-seq]
RNA-seq (gene expression) · human · 18 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 18 samples: 6 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE314447_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1391339 and SRA study SRP656682. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 18 samples.
How we read this: 6 replicated groups read from 18 sample titles; they account for 18 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9396539 DMSO-pH7.4#1 DMSO-pH7.4#
- GSM9396540 DMSO-pH7.4#2 DMSO-pH7.4#
- GSM9396541 DMSO-pH7.4#3 DMSO-pH7.4#
- GSM9396542 DMSO-pH6.5#1 DMSO-pH6.5#
- GSM9396543 DMSO-pH6.5#2 DMSO-pH6.5#
- GSM9396544 DMSO-pH6.5#3 DMSO-pH6.5#
- GSM9396545 IACS16559-pH7.4#1 IACS16559-pH7.4#
- GSM9396546 IACS16559-pH7.4#2 IACS16559-pH7.4#
- GSM9396547 IACS16559-pH7.4#3 IACS16559-pH7.4#
- GSM9396548 IACS16559-pH6.5#1 IACS16559-pH6.5#
- GSM9396549 IACS16559-pH6.5#2 IACS16559-pH6.5#
- GSM9396550 IACS16559-pH6.5#3 IACS16559-pH6.5#
- GSM9396551 CCS1477-pH7.4#1 CCS1477-pH7.4#
- GSM9396552 CCS1477-pH7.4#2 CCS1477-pH7.4#
- GSM9396553 CCS1477-pH7.4#3 CCS1477-pH7.4#
- GSM9396554 CCS1477-pH6.5#1 CCS1477-pH6.5#
- GSM9396555 CCS1477-pH6.5#2 CCS1477-pH6.5#
- GSM9396556 CCS1477-pH6.5#3 CCS1477-pH6.5#
- GSE314449 Low physiological pH drives P300-mediated acetylation of PARP1 and promotes PARP inhibitor resistance 22 samples shares parp1, parp, physiological, p300-mediated, acetylation, resistance, inhibitor, promotes
- GSE314448 Low physiological pH drives P300-mediated acetylation of PARP1 and promotes PARP inhibitor resistance [Cut & Run] 4 samples shares parp1, parp, physiological, p300-mediated, acetylation, resistance, inhibitor, promotes
- GSE322780 PARP1 Suppression Drives ROS Resistance in Aneuploid Cancer Cells 46 samples shares parp1, parp, resistance
- GSE236167 PARP15 promotes vascular barrier integrity in inflammation 16 samples shares parp1, parp, promotes
- GSE243141 Codon Specific Readthrough as a Mechanism of BRCA2 Restoration in Acquired PARP Inhibitor and Chemotherapy Resistance [RNA-seq] 10 samples shares parp, resistance, inhibitor
- GSE212435 Targeting STAT3-FoxO1 axis reverses de novo and acquired PARP inhibitor resistance independent of BRCA status 31 samples shares parp, resistance, inhibitor
- GSE243143 Codon Specific Readthrough as a Mechanism of BRCA2 Restoration in Acquired PARP Inhibitor and Chemotherapy Resistance 13 samples shares parp, resistance, inhibitor
- GSE212431 Targeting STAT3-FoxO1 axis reverses de novo and acquired PARP inhibitor resistance independent of BRCA status [RNA-seq] 8 samples shares parp, resistance, inhibitor
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.